<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/473F7B5C-70FE-4079-A7A4-9B33054D3495"><gtr:id>473F7B5C-70FE-4079-A7A4-9B33054D3495</gtr:id><gtr:name>University of Rome I (La Sapienza)</gtr:name><gtr:address><gtr:line1>University of Rome</gtr:line1><gtr:line2>Via Pietro Roselli</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/473F7B5C-70FE-4079-A7A4-9B33054D3495"><gtr:id>473F7B5C-70FE-4079-A7A4-9B33054D3495</gtr:id><gtr:name>University of Rome I (La Sapienza)</gtr:name><gtr:address><gtr:line1>University of Rome</gtr:line1><gtr:line2>Via Pietro Roselli</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7C4BB0AE-8181-4FB7-84D1-897AC84FFC9F"><gtr:id>7C4BB0AE-8181-4FB7-84D1-897AC84FFC9F</gtr:id><gtr:firstName>Guido</gtr:firstName><gtr:surname>Franzoso</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C256EE23-D784-4AFF-B2E9-3528A390EE5A"><gtr:id>C256EE23-D784-4AFF-B2E9-3528A390EE5A</gtr:id><gtr:firstName>Menotti</gtr:firstName><gtr:surname>Ruvo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7E7E01E5-B0FD-488E-B9EB-969462D0379F"><gtr:id>7E7E01E5-B0FD-488E-B9EB-969462D0379F</gtr:id><gtr:firstName>Caroline</gtr:firstName><gtr:surname>Low</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F26612C6-66DE-4431-8EA1-59177A1B5570"><gtr:id>F26612C6-66DE-4431-8EA1-59177A1B5570</gtr:id><gtr:firstName>Catherine</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Tralau Stewart</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0901436"><gtr:id>93103C03-909A-403C-ABCA-8FC729FE4158</gtr:id><gtr:title>Development of Gadd45b-Targeting Agents for Multiple Myeloma Therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901436</gtr:grantReference><gtr:abstractText>Professor Guido Franzoso and his colleagues at Imperial College have discovered a new way of tackling multiple myeloma, a cancer of the bone marrow, which could offer a cure for this disease. In contrast, existing drugs have severe side effects that limit the doses that can be given. The most recent treatment, bortezomib (Velcade) cannot kill all of the cancer, allowing some of the cancer cells to escape and, whilst the disease can be temporarily stabilised, relapse is inevitable. As a result, most of the 110,000 people diagnosed each year with the disease in US, Europe and Japan will die about 3-5 years later. This blood borne cancer cannot be treated using radiotherapy or surgery and so the options are restricted to chemotherapy or bone marrow transplant. We have discovered a new protein, called Gadd45b, which forms one half of a crucial molecular link between cells. An enzyme called MKK7 controls traffic in a second signalling pathway (JNK) and, bound together, these two molecules stop the signals that tell normal bone marrow cells to die, allowing them to multiply uncontrollably. We have designed small molecules that prevent the two proteins from binding to one another. Multiple myeloma cancer cells contain high levels of Gadd45b, compared to normal bone marrow, and we have already shown that we can kill human myeloma cells in the laboratory by preventing Gadd45b from binding to its partner, MKK7. We have shown that these proteins don?t affect normal cells, making them promising starting points in the search for a new drug therapy. The next steps will be to find out how these molecules behave in models of cancer, and use this information to create a second generation of improved molecules. At the end of this study we aim to create a compound that can be given to patients within a year or two. This treatment will not only stabilise the disease, but may actually offer a cure for multiple myeloma. The team has wide experience of successful drug discovery and development within the pharmaceutical industry and will develop the peptide molecules using Imperial College?s extensive biological, chemical and clinical facilities.</gtr:abstractText><gtr:technicalSummary>Despite the recent introduction of new therapies and significant improvements in patient outcomes, Multiple Myeloma (MM) remains incurable. NF-kB-targeting strategies have promised much in recent years, but failed to produce a cure. Even with these, disease relapse and onset of drug resistance inevitably follow the initial response. This is because conventional NF-kB inhibitors have small therapeutic indices, owing to indiscriminate targeting of the proteasome/NF-kB pathway, which prevents these potentially effective therapies from being used clinically at doses that can achieve disease eradication. This limitation reveals a need for a radically new therapeutic approach, one that is more specific, safer, hence more effective. To deliver this unmet need in MM, we have developed new peptide leads which selectively kill MM cells, without toxicity to healthy cells. Our approach targets discrete downstream effectors of NF-kB, rather than NF-kB itself, and so inhibits NF-kB?s survival functions, while leaving its other functions in inflammation, immunity and development intact. Due to this high selectivity, coupled with high solubility and good safety profiles, our lead compounds provide opportunity for therapy that can be delivered at doses required to cure. We already have proof of mechanism with specific activity in primary MM cells. We will optimize these leads to develop new, clinically useful compounds, validated in xenograft models. This will pave the way to Phase-I trials.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>650482</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sapienza University of Rome</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Physics</gtr:department><gtr:description>Definition of the putative mDTP-binding pocket of the Gadd45b/MKK7 complex</gtr:description><gtr:id>245422F3-F520-430C-AD32-C78FFCA9EC94</gtr:id><gtr:impact>This collaboration has enabled us to generate an improved model of the Gadd45b/MKK7 complex and identify the putative mDTP-binding pocket of the Gadd45b/MKK7 complex. This collaboration is multi-disciplinary. It requires expertise in chemistry, structural biology, bioinformatics, and molecular and cellular biology.</gtr:impact><gtr:piContribution>We synthesized and tested 120 compounds to generate a robust pharmacophore. Our collaborator has generated an improved model of the Gadd45b/MKK7 complex and using sophisticated docking software has identified the putative mDTP-binding pocket of the Gadd45b/MKK7 complex.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London (ICL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Drug Discovery Centre</gtr:department><gtr:description>lead optimization</gtr:description><gtr:id>47CFB62F-2EAD-46D6-8400-C4644C253176</gtr:id><gtr:impact>We have obtained compounds with improved activity in vitro and in cells. These compounds show good bioavailability in mice. We have used them to obtain proof of concept for our approach in multiple myeloma xenografts in mice. This collaboration is multi-disciplinary. It requires expertise in chemistry, pharmacology, molecular and cellular biology, and disease pathogenesis.</gtr:impact><gtr:piContribution>We have contributed to the design and synthesis of compounds with improved activity and PK properties. We have tested these compounds through the in vitro and in vivo cascade described in Milestone 1. We have used these compounds to obtain proof of concept for our approach in mice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This patent was filed as a background patent to the MRC funded work.
The patent claims novel peptide-based agents which target the Gadd45beta/MKK7 interaction, stimulating apoptosis for use in treating multiple myeloma.</gtr:description><gtr:id>028680A0-DD23-4FBC-8D74-CAD4AF97F40E</gtr:id><gtr:impact>The patent has also been filed in various national/regional territories including USA, Europe, Canada, Australia, BRIC nations, Rep of Korea, Japan, Mexico, Israel and South Africa.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2011/048390</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Gadd45Beta tageting agents</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This patent claims the discovery of Gadd45beta as a marker of disease in multiple myeloma and the method of measuring the protein to diagnose disease, prognosis and whether a patient is suited for treatment using targeted peptide-based therapeutics.</gtr:description><gtr:id>76AD79E6-34E3-48C5-A51B-7CA163711031</gtr:id><gtr:impact>The patent has also been filed in various national/regional territories, including USA, Europe, Canada, Australia, Japan</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2012/146940</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Method of Diagnosis and Prognosis</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Current funding is MRC Biomedical Catalyst grant MR/L005069/1.
Current stage is Initial Development.
The intervention is a peptide drug designed to block the Gadd45b/MKK7 interaction to treat multiple myeloma.</gtr:description><gtr:id>A5904D16-E01E-4811-8FB2-77F55B0B25EF</gtr:id><gtr:impact>This product is currently in development. Whilst very promising, it has not currently been in patients.</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Further validation of peptides trargetting the Gadd45b/MKK7 interaction</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>using mouse s.c. and orthotopic xenograft models, we have obtained proof of concept that DTP3 therapy will be safe and effective against multiple myeloma</gtr:description><gtr:id>F35E485C-C50E-45FC-83F7-77D7AF03A0D6</gtr:id><gtr:impact>These results supported the further development of DTP3 into clinical trials. In preparation for these trials, we have undertaken a parallel programme to develop new biomarkers enabling to predict patient responder populations and identify patient populations at higher risk of rapid disease progression in multiple myeloma.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>proof of concept in mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>several multiple myeloma cell lines expressing Gadd45b-specific or MKK7-specific sh-RNAs</gtr:description><gtr:id>3997F89B-DC56-4463-8250-F4B559E8F4F0</gtr:id><gtr:impact>these cell line have enabled us to establish the relevance of Gadd45b to multiple myeloma pathogenesis and the high target specificity of DTP3 for the Gadd45b/MKK7 complex.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>engineered multiple myeloma cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>as part of the project, we have synthesized and tested 120 mDTPs.</gtr:description><gtr:id>350928EA-DDD7-4822-A6A2-49948F8E9081</gtr:id><gtr:impact>the analysis of these 120 compounds through the in vitro and in vivo activity cascade described in Milestone has enabled us to refine our modeled pharmacophore and gather important information on the relationship between structure and activity of mDTPs.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>novel mDTPs</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>using refined structural information and sophisticated bioinformatics tools, we identify the pocket on the Gadd45b/MKK7 complex that binds to mDTPs.</gtr:description><gtr:id>8D04A16A-FC97-489E-BBC0-393008617D12</gtr:id><gtr:impact>This result will enable us to predict amino acid mutations of Gadd45b or MKK7 that could contribute to the onset of resistance to mDTP-based therapy in patients with multiple myeloma.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>identification of the Gadd45b/MKK7-binding pocket of mDTPs</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Kesios Therapeutics Ltd</gtr:companyName><gtr:description>Spinout company formed by Imperial Innovations focussed on the development of therapeutics targeting the novel Gadd45beta/MKK7 interaction for multiple myeloma, haematological cancers and other indications.</gtr:description><gtr:id>DDA92892-92D1-4B82-9255-2AD7F6E351BC</gtr:id><gtr:impact>In October 2014, Imperial Innovations has completed an aggregate seed investment of &amp;pound;1.85million into Kesios Therapeutics Ltd. In October 2015, Kesios Therapeutics Ltd. secured an additional aggregate Series A investment of &amp;pound;19 million</gtr:impact><gtr:yearCompanyFormed>2012</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2AD43D7-2349-49FE-A0C8-388695B7FCA5"><gtr:id>C2AD43D7-2349-49FE-A0C8-388695B7FCA5</gtr:id><gtr:title>Cancer-selective targeting of the NF-?B survival pathway with GADD45?/MKK7 inhibitors.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8ec8fa16240cc29e850d8213f6927c99"><gtr:id>8ec8fa16240cc29e850d8213f6927c99</gtr:id><gtr:otherNames>Tornatore L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/954E9E66-8664-4441-9F8B-B88D68D6A649"><gtr:id>954E9E66-8664-4441-9F8B-B88D68D6A649</gtr:id><gtr:title>Cancer: NF-?B regulates energy metabolism.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e99a0dfb0dc5c8a03a5deed1f2cb0bae"><gtr:id>e99a0dfb0dc5c8a03a5deed1f2cb0bae</gtr:id><gtr:otherNames>Moretti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DE97CB9E-36DA-49A1-9000-700DBB7ED908"><gtr:id>DE97CB9E-36DA-49A1-9000-700DBB7ED908</gtr:id><gtr:title>The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation.</gtr:title><gtr:parentPublicationTitle>Trends in cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8ec8fa16240cc29e850d8213f6927c99"><gtr:id>8ec8fa16240cc29e850d8213f6927c99</gtr:id><gtr:otherNames>Tornatore L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0962-8924</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901436</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>